Two doses of the CoronaVac vaccine developed by Chinese drug maker Sinovac offer 83.5 percent protection against symptomatic COVID-19, according to a new study published in the top medical journal The Lancet.
A large-scale randomized controlled phase-3 trial of the inactivated vaccine, involving over 10,000 participants aged 18 to 59, was conducted in Turkey between September and January. The participants were given two doses of CoronaVac 14 days apart.
Interim data from the trial suggests that the vaccine is safe and induces a robust immune response.
Most or 90 percent of the reported adverse effects were mild, including fatigue, pain at the injection site and muscle pain, occurring within seven days of an injection. No severe adverse effects were recorded during the study period.
Stored and transported at 2 to 8 degrees Celsius, the vaccine has been approved for emergency use in more than 20 countries.